Nocion Therapeutics said that it has raised an additional $23 million, expanding a Series B financing that raised $62 million in 2024 for development of the company’s taplucainium DPI for the treatment of chronic cough. The company initiated the Phase 2b ASPIRE trial of taplucainium in patients with chronic cough in 2024 and says that it expects top-level results from that study in mid-2026. The additional funding will support post-trial activities and preparations for Phase 3 development, the company said.
Nocion CEO Richard Batycky commented, “We have made excellent progress enrolling patients in the ASPIRE Phase 2b trial and anticipate topline results in mid-2026. This financing gives us the runway to continue preparations for later-stage development as we look to position taplucainium as one of the leading potential treatments for the millions of people who suffer from chronic cough.”
Read the Nocion Therapeutics press release
